Oculus Innovative
Sciences, Inc. OCLS, a global healthcare company that designs,
manufactures and markets prescription and non-prescription products in 33
countries, today announced that the company's Microcyn® Negative-Pressure
Wound Therapy Solution™ received a "strong consensus" rating for use with
Kinetic Concepts Inc.'s (KCI) Negative Pressure Wound Therapy with
Instillation (NPWTi) as identified in the First International Consensus
Guidelines.
The guidelines were published in the December 2013 issue of Journal of Plastic
and Reconstructive Surgery. In addition to Microcyn, only one other irrigation
solution available in the United States also received strong consensus
(greater than 80% agreement of the panel) for use with NPWTi. That product is
a broad-spectrum, polynexanide-based antimicrobial solution.
Other solutions reviewed, including acetic acid, sodium hypochlorite, silver
nitrate and saline, did not achieve the panel support necessary for a "strong
consensus" rating from the group.
The international consensus panel, convened by MedStar Georgetown University
Hospital (through an unrestricted educational grant from KCI), provides the
first authoritative guidance on the appropriate use of NPWTi. The guidelines
include nine major consensus statements that provide clinical guidance in the
following areas:
* Appropriate wound types that would benefit from instillation therapy
* Importance of debridement for acutely infected, chronically infected, or
contaminated wounds
* Appropriate instillation solutions, volume of solution and soak time
* Appropriate pressure settings and modes
* Optimal duration of NPWTi
"We're honored that Microcyn's safety and efficacy in a negative pressure
wound therapy setting has generated such overwhelming support from a truly
premiere slate of healthcare professionals," said Dr. Robery Northey, Oculus'
vice president of research and development. "Our research and development team
continues to work diligently to create a variety of Microcyn-based solutions
that are safe and compatible in a broad array of indications and devices,
including negative pressure instillation."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in